Stage 4 EGFR Mutation Lung Cancer: 74 Real Stories

Stage IV EGFR Lung Cancer: Marnie's Patient Story

Patient Info: Marnie Clark, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: brain

Two years after diagnosis, Marnie reported that the brain tumor was gone, her leg was almost back to normal, and her first targeted medication continued to control the lung cancer.

Stage IV EGFR Non-Small Cell Lung Cancer: Rachael's Patient Story

Patient Info: Rachael Malmberg, Female | Stage IV

Biomarkers: EGFR-positive; specific alteration not reported

Rachael remained highly active, working full time, leading radon-advocacy organizations, and raising her 6-year-old daughter while living with Stage IV EGFR-positive NSCLC.

Stage IV EGFR Non-Small Cell Lung Cancer: Valerie's Patient Story

Patient Info: Valerie Brown, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Valerie was stable for more than 20 months on targeted therapy for Stage IV EGFR exon 19-deleted lung adenocarcinoma.

Stage IV EGFR Non-Small Cell Lung Cancer: Lexi's Patient Story

Patient Info: Lexi, Female, Under 40 | Stage IV

Biomarkers: EGFR exon 20 mutation

Metastatic Site: Bone — left leg and hip

Living with Stage IV EGFR exon 20 metastatic NSCLC involving bone, after chemotherapy, targeted therapy, a drug trial, and surgery to remove the primary lung mass; latest disease-control status is not clearly stated.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Bill's Patient Story

Patient Info: Bill, Male | Stage IV

Biomarkers: EGFR exon 21 mutation

Metastatic Site: Spine; brain; hips/bone

Stage IV EGFR exon 21 lung cancer improved in brain and spine on osimertinib, but later lung-mass growth led to clinical-trial treatment; Bill remained active in advocacy and felt positive about progress.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Gerri's Patient Story

Patient Info: Gerri, Female | Stage IV

Biomarkers: EGFR-positive / EGFR-mutated

Metastatic Site: Not reported

Living actively with Stage IV EGFR-positive NSCLC after wedge resection and unnamed EGFR-directed targeted therapy, with major hiking and travel goals continuing after diagnosis.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Lung Cancer: Dann's Patient Story

Patient Info: Dann Wonser, Male, 40s | Stage IV

Biomarkers: EGFR mutation; T790M mutation

Metastatic Site: Not reported

Dann Wonser passed away on June 30, 2024, 18 years after being diagnosed at age 49 with Stage IV EGFR/T790M-mutated lung cancer.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Rhonda's Patient Story

Patient Info: Rhonda Martin, Female | Stage IV

Biomarkers: EGFR-positive mutation

Metastatic Site: Brain; spine; hip bone; lymph nodes; cerebrospinal…

Rhonda Martin passed away on January 9, 2023 from complications of Stage IV EGFR-positive lung cancer, nearly 5 years after diagnosis in March 2018.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Lung Cancer: Anne's Patient Story

Patient Info: Anne, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: spine; hips; lymph nodes; liver

Anne maintained a good quality of life for about 1 year on an oral EGFR-targeted medicine and later entered a clinical trial while continuing lung-cancer advocacy.

The Patient StoryRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Rosee's Patient Story

Patient Info: Rosee, Female | Stage IV

Biomarkers: EGFR mutation; specific variant not reported

Metastatic Site: brain

Within weeks of starting osimertinib, Rosee’s tumors shrank significantly, migraines and vertigo resolved, and hearing began to return; she remained on treatment and active in advocacy.

Lung Cancer Research FoundationRead more →

Stage IV EGFR Lung Cancer: Shannon's Survivor Story

Patient Info: Shannon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; TP53 mutation

Metastatic Site: cervical spine (C1/C2 and C4/C6), liver

As of June 2026, Shannon described no evidence of active disease: visible tumors were gone, the original lung mass had decreased from 10.8 cm to a 3.8 cm cavity, and targeted therapy continued to suppress possible remaining cells.

The Patient StoryRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

EGFR-mutated Stage IV lung cancer with later brain progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR C797S mutation; acquired ROS1 rearrangement

Metastatic Site: brain|bone

She died about 20 months after diagnosis after brain progression and a severe postoperative stroke.

PubMed CentralRead more →

EGFR-mutated lung cancer responds after acquired ROS1 resistance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; acquired ROS1 rearrangement

Metastatic Site: pleura

She remained on osimertinib plus crizotinib with a sustained clinical and radiologic response for more than 18 months.

PubMed CentralRead more →

Stage IVA EGFR-mutated lung adenocarcinoma: stable disease on first-line osimertinib

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; baseline EGFR exon 20 T790M mutation; ALK IHC negative; PD-L1 TPS 30%; TTF-1-positive

Metastatic Site: pleura; malignant pleural-pericardial adhesions

As of April 2026, she had stable disease for more than 9 months on first-line osimertinib, with no progressive disease, no recurrent pleural effusion, ECOG improvement from 2 to 0, and no treatment-related adverse events.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation; later ALK mutation after progression

Metastatic Site: Bone — pelvis and spine/L5

Living with Stage IV lung cancer on a clinical trial after progression, with current treatment described as working and quality of life improved.

The Patient StoryRead more →

Stage IV EGFR-positive lung cancer treated for nearly 5 years before progression

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver

The cancer later progressed despite chemotherapy, and he died from lung cancer 4 years and 8 months after diagnosis.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Maggie's Patient Story

Patient Info: Maggie, Female, 60s | Stage IV

Biomarkers: EGFR mutation; MET amplification resistance mutation; MET overexpression

Metastatic Site: Brain

Maggie initially reached no evidence of disease on EGFR-targeted therapy, but later had repeated progression, including MET-amplification resistance and MET overexpression, requiring SBRT, a clinical trial, chemotherapy, and later-line targeted treatment.

The Patient StoryRead more →

EGFR L858R lung adenocarcinoma with rapid neurologic decline

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR L858R mutation; CK7-positive; Napsin A-positive; TTF-1-positive; p40-negative; Ki-67 about 1%

Metastatic Site: brain parenchyma and meninges

The patient developed rapidly progressive cognitive decline with multifocal brain lesions. Lung biopsy confirmed EGFR L858R lung adenocarcinoma, and she received amivantamab, but neurologic deterioration continued and she died in the fourth month of the disease course.

PubMed CentralRead more →

Stage 4 lung cancer: never-smoker with complete remission

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR20ins mutation; TP53 p.Q192 mutation; PD-L1 TPS 0%; CPS 0%

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bilateral…

The patient had a durable response to high-dose furmonertinib, later developed a right cerebellar metastasis treated with stereotactic radiation, and continued to benefit from furmonertinib as of April 2025 with 27 months of progression-free survival reported.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma With Bone and Leptomeningeal Metastases

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: bone, leptomeninges

In May 2025, leptomeningeal disease remained present and he continued combination chemotherapy with bevacizumab and high-dose furmonertinib, leaving hospital in stable condition after cycle 8.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Jennifer's Patient Story

Patient Info: Jennifer, Female | Stage IV

Biomarkers: EGFR genomic mutation

Metastatic Site: Not reported

Jennifer is alive more than 5.5 years after a Stage IV adenocarcinoma diagnosis, continuing EGFR-targeted treatment and living with ongoing side effects and surveillance needs.

The Patient StoryRead more →

Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion: stable disease on ivonescimab plus pemetrexed

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion persisted. Later pleural fluid had PD-L1 TPS 40% / CPS 41, low TMB

Metastatic Site: pleura / malignant pleural effusion

As of August 2025, Stage IVA EGFR-mutated lung adenocarcinoma with malignant pleural effusion was stable on ivonescimab plus pemetrexed after prior progression on gefitinib, almonertinib, and ivonescimab monotherapy.

PubMed CentralRead more →

Stage IVB EGFR L861R lung adenocarcinoma treated with afatinib, osimertinib, and chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861R mutation; CEA 5.5 ng/mL; CYFRA 21-1 5.1 ng/mL

Metastatic Site: lymph nodes, lung, bone

As of September 2025, the patient remained alive 27 months after diagnosis after multiple EGFR-targeted and chemotherapy lines.

PubMed CentralRead more →